Pancrelipase is a purified form of porcine pancreatic lipase, amylase, and protease enzymes used to treat malabsorption associated with pancreatic insufficiency resulting from cystic fibrosis and pancreatitis. Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases.
- Mechanism
- Curator reviewed · 1 reference
Pancrelipase is used to replace the deficiency of pancreatic enzymes. As abovementioned, pancrelipase is formed by a mixture of lipase, protease, and amylase which are able to break down fat, protein, and starches, respectively, in the small intestine. For a more specific description of each mechanism of action, please visit DB11065, DB11066 and DB13147.
- Primary indication
- The use of pancrelipase amylase is part of the pancreatic enzyme replacement therapy.Curator reviewed · 42 structured indications
- Formula / weight
- 131000.0 Da
- First approval
- Canada, 2018
- Also known as
- Pancrealipase · Pancreatic extract pancrelipase · Pancreatic protease · Pancreatin · Pancrelipase (amylase;lipase;protease)
- Code names
- EUR-1008 · EUR-1066 · SA-001
Resolves to
What you can answer from here — as of October 01, 2026
Which other approved drugs treat the same conditions as Pancrelipase, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account